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Low haematocrit values are generally well tolerated in terms of oxygen transport but a low
haematocrit might interfere with blood coagulation. We thus sampled 60 ml of blood in 30
healthy volunteers. The blood was centrifuged for 30 min at 2000 g and separated into plasma,
which contained the platelet fraction, and packed red blood cells. The blood was subsequently
reconstituted by combining the entire plasma fraction with a mixture of packed red blood cells,
0.9% saline, so that the ®nal haematocrit was either 40, 30, 20, or 10%. Blood coagulation was
assessed by computerized Thrombelastographâ analysis. Data were compared using repeated
measures analysis of variance and post-hoc paired t-tests with Bonferroni correction.
Decreasing the haematocrit from 40 to 10% resulted in a shortening of reaction time (r) and
coagulation time (k), and an increase in angle a, maximum amplitude (MA) and clot strength
(G) (all P<0.02). This pattern represents acceleration of blood coagulation with low haemato-
crit values. The isolated reduction in haematocrit, therefore, does not compromise in vitro
blood coagulation.
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Avoiding allogeneic blood transfusions1 2 and avoiding
hypovolaemia3 4 is important in the perioperative care of
surgical patients. A treatment strategy tailored to both of
these aims will result in periods of low haematocrit in
patients undergoing surgical procedures associated with
signi®cant blood loss. In general, such acute haemodilution
is well tolerated5 but there are recent publications that raise
concerns that a low haematocrit might compromise blood
coagulation6±8 and even recommend allogeneic blood
transfusion to raise the haematocrit at least to 30% just to
optimize blood coagulation.6 It is indeed known that large
volume infusions of colloids progressively compromise
blood coagulation.9±11 In contrast, moderate haemodilution
with crystalloids may accelerate blood coagulation.9 12 13
We thus studied the effect of a progressive reduction in
haematocrit per se on blood coagulation.
Materials and methods
With approval of the Anaesthesia and Surgery Ethics
Committee of the University Hospital Zurich and written
informed consent, 30 healthy volunteers (24±51 yr of age)
were enrolled into this study. Exclusion criteria were known
cardiovascular, lung or liver diseases, history of bleeding
diathesis, known alcohol, drug or nicotine abuse, treatment
with heparin, or acetylsalicylic acid within 5 days before the
study and treatment with non-steroidal anti-in¯ammatory
drugs within 24 h of the study.
A total of 60 ml of blood was collected in six 10 ml
graduated polypropylene tubes (Milian S.A., Geneva,
Switzerland) containing 1 ml of buffered sodium citrate
(0.129 M). Five aliquots were centrifuged for 30 min at
2000 g. The remaining aliquot served as the reference to
determine the effect, if any, of blood handling, centrifug-
ation and pipetting on blood coagulation. After centrifug-
ation, the initial haematocrit was determined directly in the
graduated tube. The blood was separated into packed red
blood cells and platelet poor plasma with the entire buffy
coat, i.e. plasma containing virtually all the platelets. In one
of these aliquots, the blood was reconstituted without
haematocrit manipulation. In the remaining four aliquots, a
part of the packed red blood cells was replaced with 0.9%
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saline so that the ®nal haematocrit, after mixing with the
entire plasma and platelet fraction, yielded a ®nal
haematocrit of 40, 30, 20, or 10%, respectively. Platelets,
haemoglobin, and haematocrit were subsequently measured
in the reconstituted blood (Coulterâ Ac T8, Coulter
Corporation, Miami, FL, USA).
Blood coagulation was assessed using a computerized
Thrombelastographâ Coagulation Analyser (CTEGâ
#3000, Haemoscope, Morton Grove, IL, USA) with celite
activation.14 The following variables of the TEGâ trace
were analysed: reaction time (r, normal value 12.0 (2.3)
mm)Ðthe time from the start of the recording until the
amplitude reaches 2 mm; coagulation time (k, normal value
4.2 (1.6) mm)Ðthe time from the end of reaction time (r)
until the amplitude achieves 20 mm; maximum amplitude
(MA, normal value 63.5 (4.5) mm) of the TEGâ tracing
represents the absolute strength of the clot; angle a (normal
value 60.2 (6.7)°)Ðthe angle formed by the slope of the
TEGâ tracing from the r to the k value. Clot lysis was
represented by the percentage decrease in the area under the
curve at 60 min (Lys60, normal value <15%) after MA.9
One millilitre of citrated blood was pipetted into a tube
containing 1% celite, and 340 ml of celite-activated citrated
blood was added to a TEGâ cup containing 20 ml 2 M
CaCl2 for recalci®cation. Clot strength (G) was calculated
from the MA as: G=(50003MA)/(96±MA).15 16
Statistical analysis
The effect of blood centrifugation, pipetting and reconsti-
tution was assessed by comparing TEGâ variables before
and after processing using paired t-tests. The effect of
progressive in vitro haemodilution was assessed with
repeated measures ANOVA and post-hoc paired t-test
with Bonferroni correction. Data are presented as mean
(SD). P-values less than 0.05 were considered signi®cant.
Results
Blood handling including centrifugation did not affect blood
coagulation (Table 1).
Progressive reduction of haematocrit from 40 to 10% did
not result in compromised blood coagulation as assessed by
TEGâ (Fig. 1). The platelet count was unaffected, reaction
time (r) and coagulation time (k) decreased, and angle a and
MA increased with decreasing haematocrit levels. Clot
strength (G) increased with decreasing haematocrit levels.
Clot lysis at 60 min decreased minimally with the reduction
in haematocrit.
Discussion
The current study indicates that an isolated reduction of
haematocrit does not compromise in vitro blood coagula-
tion. In contrast, with decreasing haematocrit, all TEGâ
variables unanimously changed towards an accelerated
blood coagulation pro®le resulting in increased clot
strength (G).
It was recently shown that there is virtually no thrombin
generation in the absence of platelets.17 With the addition of
red blood cells, however, thrombin generation gradually
recovered and it was speculated that red blood cells would
participate in the haemostatic process through exposure of
procoagulant phospholipids at their outer cell mem-
brane.17 18 In the presence of a normal number of platelets,
as in the current study, in vitro blood coagulation appears
not to be compromised signi®cantly by a reduced number of
red blood cells. Indeed, all TEGâ variables indicated
accelerated blood coagulation with a decreasing haemato-
crit resulting in an increased clot strength (G) (Fig. 1).
How relevant is this in vitro study for the clinical care of
surgical patients? Of course, the in vitro situation is different
from the clinical care of surgical patients, but only the
in vitro situation allows the assessment of the isolated effect
of a relevant change in haematocrit on blood coagulation. In
surgical patients, low haematocrits are usually encountered
after advanced surgical blood loss and asanguineous
infusion therapy to maintain normovolaemia. Therefore,
the patients have lost also coagulation factors and platelets.
In this situation, coagulopathy will result from decreased
levels of coagulation factors and platelets as well as
the effects of dilution with crystalloids and colloids.9
Interestingly, Mezzano and colleagues found that platelet
dysfunction and severity of renal dysfunction but not the
haematocrit were independent predictors for haemostatic
disorders in uraemic patients.19 Therefore, it may appear
somewhat simplistic to advocate the use of allogeneic red
blood cell transfusions for the speci®c purpose of optimiz-
ing blood coagulation.6
The use of TEGâ analysis may also be criticized. We
chose TEGâ analysis because, in a variety of clinical
situations, TEGâ was the most sensitive method to predict
surgical blood loss or the occurrence of bleeding
complications.20±25 TEGâ is increasingly used in studies
on blood coagulation14 15 26 and in vivo and in vitro
haemodilution results in similar TEGâ changes in
Table 1 Effect of blood centrifugation, pipetting and reconstitution
(centrifuged) on blood coagulation. Note, there are no signi®cant differences.
Hb=haemoglobin, HCT=haematocrit r=reaction time, k=coagulation time,
MA=maximum amplitude, G=clot strength and Lys60=clot lysis at 60 min
Non-centrifuged Centrifuged P
Hb (g dl±1) 14.0 (1.0) 13.9 (1.0) 0.697
HCT (%) 40.9 (2.9) 41.0 (2.9) 0.712
Platelets (109 litre±1) 183 (44) 179 (46) 0.472
r (mm) 11.6 (4.5) 11.2 (4.2) 0.473
k (mm) 4.6 (2.0) 4.4 (1.6) 0.492
Angle a (°) 62.0 (9.9) 61.9 (9.0) 0.914
MA (mm) 59.5 (5.0) 59.3 (4.0) 0.757
G (103 dynes cm±2) 8.4 (1.9) 8.3 (1.7) 0.533
Lys60 (%) 4.4 (2.0) 4.2 (1.4) 0.445
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humans.27 Interestingly, the results of the present study are
in accordance with an in vivo study in rabbits demonstrating
that a reduction of the haematocrit from 36 to 22% was not
associated with an increased blood loss because of a
subsequent standard splenic incision.8 The current study
suggests that a reduction of haematocrit even beyond this
range is not associated with signi®cantly compromised
blood coagulation. The results are also in agreement with
previous ®ndings that clot strength (G) tended to be higher
in platelet rich plasma when compared with whole blood.16
-The current study assessed the effect of an isolated
decrease in haematocrit on in vitro blood coagulation with
constant platelet count and unchanged coagulation factors.
This is different from a previous study by Egli and
colleagues.9 where the effect of a progressive in vitro
haemodilution with a concomitant dilution of platelets and
coagulation factors was investigated. Accordingly, different
results were found. At 60% haemodilution, corresponding to
a haematocrit of approximately 17%, blood coagulation was
largely unchanged and MA decreased.9 In contrast, blood
coagulation was accelerated in the current study at 20%
haematocrit with an increase in MA (Fig. 1). This may be
explained by preserved platelet count and coagulation
factors.
In conclusion, the isolated reduction of the haematocrit
appears not to compromise in vitro blood coagulation and
recommendations to raise the haematocrit to at least 30%
with the use of allogeneic blood transfusions to optimize
blood coagulation6 should be viewed with reservation
considering the potential adverse effects of allogeneic
blood transfusions.1
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